Annovis Bio is a clinical-stage drug platform company founded in 2008. They focus on developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Their approach targets the underlying causes of neurodegeneration by reducing toxic proteins and improving communication between nerve cells.

However, things may not be going according to plan as their share prices have dropped by over 50% as the results from their recent stage 2 trial have been released.

Annovis Bio was conducting a clinical trial for a new Alzheimer’s drug called Buntanetap. The drug was designed to inhibit the production of amyloid beta, tau, alpha-synuclein, and TDP43, which are all proteins that are believed to play a role in Alzheimer’s disease. According to Annovis, the trial was successful and showed significant cognitive improvement in patients with early Alzheimer’s disease.[Fierce Biotech][Yahoo Finance]

However, experts say the data from the trial is misleading. The trial did not meet its main goal, which was to improve patients’ daily activities compared to a placebo. This lack of clarity about the drug’s effectiveness spooked investors, leading to the sharp decline in Annovis’s stock price.[Fierce Biotech]

For more information use the links below.

[Fierce Biotech]
[Yahoo Finance]